Skip to main content Accessibility help

Epidemiology and cost of heart failure in children*

  • Deipanjan Nandi (a1) and Joseph W. Rossano (a1)


Heart failure in children is a complex disease process, which can occur secondary to a variety of aetiologies, including CHD, cardiomyopathy, or acquired conditions as well. Although the overall incidence of disease is low, the associated morbidity and mortality are high. Mortality may have decreased slightly over the last decade, and this is likely due to our ability to shepherd patients through longer periods of significant morbidity, with lasting effects. Costs of heart failure are significant – on the order of $1 billion annually as hospital charges for inpatient admissions alone. The value, or benefit to patient life and quality of life at this cost, is not well delineated. Further research is needed to optimise not only outcomes for these patients but also the high costs associated with them.


Corresponding author

Correspondence to: Dr D. Nandi, MD, The Children’s Hospital of Philadelphia, 34th Street & Civic Center Boulevard, Philadelphia, PA 19104, United States of America. Tel: +267 432 2674; Fax: +215 590 5825; E-mail:


Hide All

Presented at the Children’s Hospital of Philadelphia Cardiology 2015: 18th Annual Update on Pediatric and Congenital Cardiovascular Disease: “Challenges and Dilemmas”, Scottsdale, Arizona, United States of America, Wednesday February 11, 2015 – Sunday, February 15, 2015.



Hide All
1.Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240e327.
2.Law, SP, Kim, JJ, Decker, JA, et al. Hospital charges for pediatric heart transplant hospitalizations in the United States from 1997 to 2006. J Heart Lung Transplant 2012; 31: 485491.
3.Dayton, JD, Kanter, KR, Vincent, RN, Mahle, WT. Cost-effectiveness of pediatric heart transplantation. J Heart Lung Transplant 2006; 25: 409415.
4.O’Connor, MJ, Rossano, JW. Ventricular assist devices in children. Curr Opin Cardiol 2014; 29: 113121.
5.Rossano, JW, Kim, JJ, Decker, JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 2012; 18: 459470.
6.Nandi, D, Lin, K, O’Connor, M, et al. Hospital Charges for Pediatric Heart Failure Related Hospitalization Admissions in the United States from 2000 to 2009. In Press, Pediatric Cardiology, 2015.
7.Mozaffarian, D, Benjamin, EJ, Go, AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015; 131: e29e322.
8.Heidenreich, PA, Albert, NM, Allen, LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606619.
9.Frankel, DS, Vasan, RS, D’Agostino, RB, et al. Resistin, adiponectin, and risk of heart failure. J Am Coll Cardiol 2009; 53: 754762.
10.Damasceno, A, Mayosi, BM, Sani, M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012; 172: 13861394.
11.Rossano, JW, Shaddy, RE. Heart failure in children: etiology and treatment. J Pediatr 2014; 165: 228233.
12.Massin, MM, Astadicko, I, Dessy, H. Epidemiology of heart failure in a tertiary pediatric center. Clin Cardiol 2008; 31: 388391.
13.Rossano, JW, Goldberg, DJ, Mott, AR, et al. The burden of heart failure related hospitalizations in children with single ventricle heart disease in the United States (abstract). Circulation 2012; 126 (Suppl 21): A11975.
14.Lipshultz, SE, Sleeper, LA, Towbin, JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 16471655.
15.Nugent, AW, Daubeney, PE, Chondros, P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 16391646.
16.Andrews, RE, Fenton, MJ, Ridout, DA, Burch, M, British Congenital Cardiac Association. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation 2008; 117: 7984.
17.Wilkinson, JD, Landy, DC, Colan, SD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 Years. Heart Fail Clin 2010; 6: 401413.
18.Tsirka, AE, Trinkaus, K, Chen, SC, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 2004; 44: 391397.
19.Maron, BJ, McKenna, WJ, Danielson, GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 16871713.
20.Colan, SD, Lipshultz, SE, Lowe, AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115: 773781.
21.Webber, SA, Lipshultz, SE, Sleeper, LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation 2012; 126: 12371244.
22.Wouters, KA, Kremer, LCM, Miller, TL, Herman, EH, Lipshultz, SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561578.
23.Wittlieb-Weber, CA, Lin, KY, Zaoutis, TE, et al. Pediatric versus adult cardiomyopathy and heart failure–related hospitalizations: a value-based analysis. J Card Fail 2015; 21: 7682.
24.Dipchand, AI, Edwards, LB, Kucheryavaya, AY, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33: 985995.
25.Towbin, JA, Lowe, AM, Colan, SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 18671876.
26.Alexander, PMA, Daubeney, PEF, Nugent, AW, et al. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy. Circulation 2013; 128: 20392046.
27.Pahl, E, Sleeper, LA, Canter, CE, et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy. J Am Coll Cardiol 2012; 59: 607615.
28.Bharucha, T, Lee, KJ, Daubeney, PEF, et al. Sudden death in childhood cardiomyopathy. J Am Coll Cardiol 2015; 65: 23022310.
29.Everitt, MD, Sleeper, LA, Lu, M, et al. Recovery of echocardiographic function in children with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2014; 63: 14051413.
30.Shaddy, RE, Boucek, MM, Hsu, DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298: 11711179.
31.Daubeney, PE, Nugent, AW, Chondros, P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 2006; 114: 26712678.
32.O’Sullivan, JJ, Roche, SL, Crossland, DS, Chaudhari, MP, Kirk, RC, Asif, H. Recovery of heart function in children with acute severe heart failure. Transplantation 2008; 85: 975979.
33.Lipshultz, SE, Orav, EJ, Wilkinson, JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013; 382: 18891897.
34.Maron, BJ, Olivotto, I, Spirito, P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102: 858864.
35.Grupper, A, Park, SJ, Pereira, NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant 2015; 34: 10421049.
36.Hershberger, RE, Lindenfeld, J, Mestroni, L, et al. Genetic evaluation of cardiomyopathy – a heart failure society of America practice guideline. J Card Fail 2009; 15: 8397.
37.Mahle, WT, Ianucci, G, Vincent, RN, Kanter, KR. Costs associated with ventricular assist device use in children. Ann Thorac Surg 2008; 86: 15921597.
38.Mahle, WT, Forbess, JM, Kirshbom, PM, Cuadrado, AR, Simsic, JM, Kanter, KR. Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children. J Thorac Cardiovasc Surg 2005; 129: 10841090.
39.Feingold, B, Arora, G, Webber, SA, Smith, KJ. Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy. J Card Fail 2010; 16: 734741.
40.Porter, ME. What is value in health care? N Engl J Med 2010; 363: 24772481.
42.Drucker, NA, Colan, SD, Lewis, AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252257.
43.Isogai, T, Yasunaga, H, Matsui, H, Tanaka, H, Horiguchi, H, Fushimi, K. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail 2015; 21: 391397.
44.Hartman, ME, Linde-Zwirble, WT, Angus, DC, Watson, RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 2013; 14: 686693.


Related content

Powered by UNSILO

Epidemiology and cost of heart failure in children*

  • Deipanjan Nandi (a1) and Joseph W. Rossano (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.